These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 27742220

  • 1. Characterization of the protective immune response to Yersinia pseudotuberculosis infection in mice vaccinated with an LcrV-secreting strain of Lactococcus lactis.
    Daniel C, Titecat M, Poiret S, Cayet D, Boutillier D, Simonet M, Sirard JC, Lemaître N, Sebbane F.
    Vaccine; 2016 Nov 11; 34(47):5762-5767. PubMed ID: 27742220
    [Abstract] [Full Text] [Related]

  • 2. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV.
    Daniel C, Sebbane F, Poiret S, Goudercourt D, Dewulf J, Mullet C, Simonet M, Pot B.
    Vaccine; 2009 Feb 18; 27(8):1141-4. PubMed ID: 19135495
    [Abstract] [Full Text] [Related]

  • 3. Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model.
    Daniel C, Dewitte A, Poiret S, Marceau M, Simonet M, Marceau L, Descombes G, Boutillier D, Bennaceur N, Bontemps-Gallo S, Lemaître N, Sebbane F.
    Front Immunol; 2019 Feb 18; 10():1830. PubMed ID: 31428104
    [Abstract] [Full Text] [Related]

  • 4. A Recombinant Attenuated Yersinia pseudotuberculosis Vaccine Delivering a Y. pestis YopENt138-LcrV Fusion Elicits Broad Protection against Plague and Yersiniosis in Mice.
    Singh AK, Curtiss R, Sun W.
    Infect Immun; 2019 Oct 18; 87(10):. PubMed ID: 31331960
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.
    Sun W, Sanapala S, Henderson JC, Sam S, Olinzock J, Trent MS, Curtiss R.
    Infect Immun; 2014 Oct 18; 82(10):4390-404. PubMed ID: 25114109
    [Abstract] [Full Text] [Related]

  • 7. CD8(+) T cells specific to a single Yersinia pseudotuberculosis epitope restrict bacterial replication in the liver but fail to provide sterilizing immunity.
    Shen H, Gonzalez-Juarbe N, Blanchette K, Crimmins G, Bergman MA, Isberg RR, Orihuela CJ, Dube PH.
    Infect Genet Evol; 2016 Sep 18; 43():289-96. PubMed ID: 27268148
    [Abstract] [Full Text] [Related]

  • 8. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
    Wang S, Goguen JD, Li F, Lu S.
    Vaccine; 2011 Sep 09; 29(39):6802-9. PubMed ID: 21199697
    [Abstract] [Full Text] [Related]

  • 9. Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against Rhodococcus equi infection.
    Cauchard S, Bermúdez-Humarán LG, Blugeon S, Laugier C, Langella P, Cauchard J.
    Vaccine; 2011 Dec 09; 30(1):95-102. PubMed ID: 22019740
    [Abstract] [Full Text] [Related]

  • 10. A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice.
    Heine SJ, Franco-Mahecha OL, Sears KT, Drachenberg CB, van Roosmalen ML, Leenhouts K, Picking WL, Pasetti MF.
    J Immunol; 2019 Apr 01; 202(7):2005-2016. PubMed ID: 30787109
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model.
    Batra L, Verma SK, Nagar DP, Saxena N, Pathak P, Pant SC, Tuteja U.
    PLoS Negl Trop Dis; 2014 Dec 01; 8(12):e3322. PubMed ID: 25474358
    [Abstract] [Full Text] [Related]

  • 13. A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.
    Zhang Y, Mena P, Romanov G, Lin JS, Smiley ST, Bliska JB.
    Infect Immun; 2012 Jan 01; 80(1):206-14. PubMed ID: 22064714
    [Abstract] [Full Text] [Related]

  • 14. Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica.
    Branger CG, Torres-Escobar A, Sun W, Perry R, Fetherston J, Roland KL, Curtiss R.
    Vaccine; 2009 Aug 27; 27(39):5363-70. PubMed ID: 19596407
    [Abstract] [Full Text] [Related]

  • 15. LcrV synthesis is altered by DNA adenine methylase overproduction in Yersinia pseudotuberculosis and is required to confer immunity in vaccinated hosts.
    Badie G, Heithoff DM, Mahan MJ.
    Infect Immun; 2004 Nov 27; 72(11):6707-10. PubMed ID: 15501808
    [Abstract] [Full Text] [Related]

  • 16. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM, Sambir M, D'Arco C, Peters LA, Seegers JF, Mayer L, McCormick AA, Dattwyler RJ.
    Vaccine; 2016 Nov 11; 34(47):5768-5776. PubMed ID: 27745954
    [Abstract] [Full Text] [Related]

  • 17. YopJ-promoted cytotoxicity and systemic colonization are associated with high levels of murine interleukin-18, gamma interferon, and neutrophils in a live vaccine model of Yersinia pseudotuberculosis infection.
    Zhang Y, Bliska JB.
    Infect Immun; 2010 May 11; 78(5):2329-41. PubMed ID: 20231414
    [Abstract] [Full Text] [Related]

  • 18. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
    Foligne B, Dessein R, Marceau M, Poiret S, Chamaillard M, Pot B, Simonet M, Daniel C.
    Gastroenterology; 2007 Sep 11; 133(3):862-74. PubMed ID: 17678918
    [Abstract] [Full Text] [Related]

  • 19. CD8(+) T cells restrict Yersinia pseudotuberculosis infection: bypass of anti-phagocytosis by targeting antigen-presenting cells.
    Bergman MA, Loomis WP, Mecsas J, Starnbach MN, Isberg RR.
    PLoS Pathog; 2009 Sep 11; 5(9):e1000573. PubMed ID: 19730693
    [Abstract] [Full Text] [Related]

  • 20. A recombinant bivalent fusion protein rVE confers active and passive protection against Yersinia enterocolitica infection in mice.
    Singh AK, Kingston JJ, Murali HS, Batra HV.
    Vaccine; 2014 Mar 05; 32(11):1233-9. PubMed ID: 24486353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.